StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3058% above fair value
$249.59+2.46 (+1.00%)

Close on Nov 20, 2026Market cap $36.89BP/E 106.7Yield –

Biogen net income

Net income is the profit left for shareholders after every expense, interest and tax.

Biogen's net income for the twelve months ending Sep 30, 2026 was $347.50M, down 78.4% year over year. For fiscal 2025 it was $1.29B, down 20.8% from the year before. Over ten years it grew -9.6% a year on average. The highest annual figure on record is $5.89B in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.29B-20.8%
FY2024Dec 31, 2024$1.63B+40.6%
FY2023Dec 31, 2023$1.16B-61.9%
FY2022Dec 31, 2022$3.05B+95.8%
FY2021Dec 31, 2021$1.56B-61.1%
FY2020Dec 31, 2020$4.00B-32.1%
FY2019Dec 31, 2019$5.89B+32.9%
FY2018Dec 31, 2018$4.43B+74.5%
FY2017Dec 31, 2017$2.54B-31.4%
FY2016Dec 31, 2016$3.70B+4.4%
FY2015Dec 31, 2015$3.55B+20.9%
FY2014Dec 31, 2014$2.93B+57.6%
FY2013Dec 31, 2013$1.86B+34.9%
FY2012Dec 31, 2012$1.38B+11.8%
FY2011Dec 31, 2011$1.23B+22.8%
FY2010Dec 31, 2010$1.01B+3.6%
FY2009Dec 31, 2009$970.13M+23.9%
FY2008Dec 31, 2008$783.17M+22.7%
FY2007Dec 31, 2007$638.17M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$20.60M-104.4%
Q2 FY2026Jun 30, 2026$97.50M-84.6%
Q1 FY2026Mar 31, 2026$319.50M+32.8%
Q4 FY2025Dec 31, 2025-$48.90M-118.3%
Q3 FY2025Sep 30, 2025$466.50M+20.1%
Q2 FY2025Jun 30, 2025$634.80M+8.8%
Q1 FY2025Mar 31, 2025$240.50M-38.9%
Q4 FY2024Dec 31, 2024$266.70M+6.8%
Q3 FY2024Sep 30, 2024$388.50M–
Q2 FY2024Jun 30, 2024$583.60M-1.4%
Q1 FY2024Mar 31, 2024$393.40M+1.4%
Q4 FY2023Dec 31, 2023$249.70M-54.6%
Q3 FY2023Sep 30, 2023-$68.10M-106.0%
Q2 FY2023Jun 30, 2023$591.60M-44.1%
Q1 FY2023Mar 31, 2023$387.90M+27.7%
Q4 FY2022Dec 31, 2022$550.40M+49.5%
Q3 FY2022Sep 30, 2022$1.13B+244.7%
Q2 FY2022Jun 30, 2022$1.06B+135.9%
Q1 FY2022Mar 31, 2022$303.80M-25.9%
Q4 FY2021Dec 31, 2021$368.20M+2.9%
Q3 FY2021Sep 30, 2021$329.20M-53.1%
Q2 FY2021Jun 30, 2021$448.50M-70.9%
Q1 FY2021Mar 31, 2021$410.20M-70.7%
Q4 FY2020Dec 31, 2020$357.90M-75.1%
Q3 FY2020Sep 30, 2020$701.50M-54.6%
Q2 FY2020Jun 30, 2020$1.54B+3.2%
Q1 FY2020Mar 31, 2020$1.40B-0.7%
Q4 FY2019Dec 31, 2019$1.44B+52.1%
Q3 FY2019Sep 30, 2019$1.55B+7.0%
Q2 FY2019Jun 30, 2019$1.49B+72.4%
Q1 FY2019Mar 31, 2019$1.41B+20.1%
Q4 FY2018Dec 31, 2018$946.80M–
Q3 FY2018Sep 30, 2018$1.44B+17.8%
Q2 FY2018Jun 30, 2018$866.60M+0.4%
Q1 FY2018Mar 31, 2018$1.17B+56.9%
Q4 FY2017Dec 31, 2017-$297.40M-145.8%
Q3 FY2017Sep 30, 2017$1.23B–
Q2 FY2017Jun 30, 2017$862.80M–
Q1 FY2017Mar 31, 2017$747.60M–
Q4 FY2016Dec 31, 2016$649.20M–

More Biogen figures

See a number that looks wrong?